Major shareholders and institutional investors have committed or indicated interest for over 80% of the ongoing rights issue, securing funding for a phase 2b study. A company presentation and Q&A will be held, and the offering is limited to Sweden.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.